Effects of Lycium barbarum Polysaccharide on doxorubicin pharmacokinetics in dogs

Abstract

Abstract: AIM: To investigate whether Lycium barbarum Polysaccharide (LBP) could modify the pharmacokinetic property of the doxorubicin (DOX) in Beagle dogs.METHODS: Eight Beagle dogs were treated with LBP capsule (20 mg/kg) or vehicle for 12 continuous days. Plasma concentration of DOX in two groups is monitored after i.v. bolus injection of DOX (1.5 mg/kg) at day 7 and was determined by reverse phase-high performance liquid chromatography with a fluorescence detector. Furthermore, the enzyme activity of cytochrome P450 3A (CYP 3A) in two groups were evaluated.RESULTS: Compared with DOX group, LBP did not modify the pharmacokinetic profiles such as the area under curve and the clearance of DOX in the LPB+DOX group. However, it is proved that LBP could inhibit the activity of CYP 3A , which is a critical metabolizing enzyme of DOX. There is a slight paradox between the inhibition of LBP to CYP 3A and no influence of LBP to pharmacokinetic profiles of intravenous DOX.CONCLUSION: Co-administration of LBP inhibits CYP 3A, the metabolizing enzyme of DOX, but does not affect the pharmacokinetic profiles of intravenous DOX.

Key words: Lycuim barbarum Polysaccharide, cardiotoxicity, herb-drug interaction

CLC Number:

R927.2

YU Jian, XIN Yan-fei , GU Li-qiang, GAO Hai-yan, ZHANG Sheng, YOU Zhen-qiang, WEN Lei, CHEN Guo-can, CHEN Yun-xiang, XUAN Yao-xian. Effects of Lycium barbarum Polysaccharide on doxorubicin pharmacokinetics in dogs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 246-253.

References

[1] Signal PK, Iliskovic N, Li T, et al. Heart failure due to doxorubicin [J]. Kuwait Med J, 2001, 33(2): 111-115.
[2] Xu MF, Tang PL, Qian ZM, et al. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals [J]. Life Sci, 2001, 68(8): 889-901.
[3] Minotti G, Menna P, Salvatorell E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity [J]. Pharmacol Rev, 2004, 56(2): 185-229.
[4] Hao G, Zhou F, Liu J, et al. Protective effect of 23-hydroxybetulinic against doxorubicin-induced cardiotoxicity through the antioxidant activity in H9c2 cells [J]. Chin J Clin Pharmacol Ther, 2012,17(7): 736-740.
[5] Baldwin JR, Phillips BA, Overmyer SK, et al. Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog [J]. Cancer Chemother Pharmacol, 1992, 30(6): 433-438.
[6] Van Vleet JF, Ferrans VJ, Weirich WE. Caridac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants [J]. Am J Pathol, 1980, 99(1): 13-42.
[7] Herman EH, Ferrans VJ. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine [J]. Lab Invest, 1983, 49(1): 69-77.
[8] Mwale F, Ciobanu I, Demers CN, et al. Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats [J]. Calcif Tissue Int, 2005, 77(3): 175-179.
[9] Sepe DM, Ginsberg JP, Balls FM. Dexrazoxane as cardioprotectant in children receiving anthracyclines [J]. Oncologist, 2010, 15(11): 1220-1226.
[10] AL-Abd AM, Kim NH, Song SC, et al. A simple HPLC method for doxorubicin in plasma and tissues of nude mice [J]. Arch Pharm Res, 2009, 32(4): 605-611.
[11] Xin YF, Zhang S, Gu LQ, et al. Electrocardiographic and biochemical evidence for the cardioprotective effect of antioxidants in acute doxorubicin-induced cardiotoxicity in the beagle dogs [J]. Biol Pharm Bull, 2011, 34(10): 1523-1526.
[12] Xin YF, Zhou GL, Deng ZY, et al. Protective effect of Lycium barbarum on doxorubicin-induced cardiotoxicity [J]. Phytother Res, 2007, 21(11):1020-1024.
[13] Xin YF, Wan LL, Peng JL, et al. Alleviation of the acute doxorubicin-induced cardiotoxicity by Lycium barbarum polysaccharide through the suppression of oxidative stress [J]. Food Chem Toxicol, 2011, 49(1):259-264.
[14] Choi JS, Piao YJ, Kang KW. Effects of quercetin on the bioavailability of doxorubicin in rats: roles of CYP3A4 and P-gp inhibition by quercetin [J]. Arch Pharm Res, 2011, 34(4): 607-613.
[15] Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy [J]. Pharmacokinet, 2004, 43(15): 1127-1156.
[16] Park HS, Oh JH, Lee J, et al. Minor effects of the citrus flavonoids naringin, naringenin and quercetin, on the pharmacokinetics of doxorubicin in rats [J]. Pharmazie, 2011, 66(6):424-429.
[17] Gu S, Jiang R. Effects of Lycium Barbarum Polysaccharide on the expression of hepatocyte cytohrome P4503A in rats with alcoholic fatty liver [J]. J Chongqing Med Univ, 2007, 32(4): 371-375.
[18] Gu S, Wang PL, Jiang R. Effects of Lycium Barbarum Polysaccharide on the expression of hepatocyte cytohrome P4502E1 in rats with alcoholic fatty liver [J]. J Chongqing Med Univ, 2006, 31(5): 688-693.
[19] Van Der Hoeven T, Coon Minor J. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes [J]. J Biol Chem, 1974, 249(19): 6302-6310.
[20] Yang AK, He SM, Liu L, et al. Herbal interactions with anticancer drugs, mechanistic and clinical considerations [J]. Curr Med Chem, 2010, 17(16): 1635-1678.
[21] Xin YF, Zhou GL, Shen M, et al. Angelca sinensis: A novel adjunct to prevent doxorubicin-induced chronic cardiotoxicity [J]. Basic Clin Pharmacol Toxicol, 2007, 101(6): 421-426.
[22] Camaggi C, Comparsi R, Strocchi E, et al. Epimbicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study [J]. Cancer Chemother Pharmacol, 1988, 21(3): 221-228.
[23] Oosterbaan MJ, Dirks RJ, Vree TB, et al. Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxyl metabolites [J]. Pharm Res, 1984, 1(5): 33-38.
[24] Lee HJ, Lee MG. Effects of dexamethasome on the pharmacokinetics of adriamycin after intravenous administration to rats [J]. Res Commun Mol Pathol Pharmacol, 1999, 105(1/2): 87-96.
[25] Gustafson DL, Merz AL, Long ME. Pharmacokinetics of combined doxorubicin and paclitaxel in mice [J]. Cancer Lett, 2005, 220(2): 161-169.
[26] Asperen JV, Tellingen OV, Beijnen JH. Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography [J]. J Chromatogr B, 1998, 712(1/2): 129-143.
[27] Asensio-López MC, Lax A, Pascual-Figal DA, et al. Metformin protects against doxorubicin-induced cardiotoxicity: Involvement of the adiponectin cardiac system [J]. Free Radic Biol Med, 2011, 51(10): 1861-1871.
[28] Boutabet K, Kebsa W, Alyane M, et al. Polyphenolic fraction of Algerian propolis protects rat kidney against acute oxidative stress induced by doxorubicin [J]. Indian J Nephrol, 2011, 21(2): 101-106.
[29] Cheng D, Kong H. The effect of Lycium barbarum polysaccharide on alcohol-induced oxidative stress in rats [J]. Molecules, 2011, 16(3): 2542-2550.
[30] Greene RF, Collins JM, Jenkins JF, et al. Plasma pharmacokinetics of adriamycin and adriamycinol: implication for design of in vitro experiments and treatment protocols [J]. Can Res, 1983, 43(7): 3417-3421.
[31] Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection [J]. Prog Cardiovasc Dis, 2010, 53(2): 105-113.
[32] Shin SC, Li C, Choi JS. Effects of baicalein, an antioxidant, on the bioavailability of doxorubicin in rats: possible role of P-glycoprotein inhibition by baicalein [J]. Pharmazie, 2009, 64(9): 578-583.